Spesolimab
1368-0120
Approved small_molecule active
Quick answer
Spesolimab for Generalized Pustular Psoriasis is a Approved program (small_molecule) at Boehringer Ingelheim with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Generalized Pustular Psoriasis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active